Related Experiment Video
Updated: Jun 22, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
Published on: November 5, 2019
Bacterial meningitis vaccines: not just for kids
Renuka Verma1, Margaret C Fisher
1Pediatric Infectious Disease Section, Children's Hospital at Monmouth Medical Center, Long Branch, NJ 07740, USA. reverma@sbhcs.com
Abstract:
Bacterial meningitis remains a feared diagnosis that may lead to significant mortality and morbidity in both the developed and developing world; case fatality rates range from 10% to 50% among all age groups. Several vaccines are available (including the Haemophilus influenzae type B polysaccharide conjugate vaccine) that have proven effective in reducing the incidence of bacterial meningitis. Although a 23-valent pneumococcal polysaccharide vaccine has been available for some time, use of the 7-valent pneumococcal conjugate vaccine (PCV) has demonstrated a dramatic reduction in the incidence of invasive pneumococcal disease; despite the increase in the disease caused by nonvaccine-serotype strains, the success of the 7-valent PCV is noteworthy. A quadrivalent conjugate meningococcal vaccine has been available in the United States since 2005; although its true efficacy remains to be determined, there have been dramatic results with declining incidence in certain high-risk populations and in endemic areas.
Insights
Vaccines significantly reduce bacterial meningitis incidence and mortality. Conjugate vaccines, like PCV and meningococcal vaccines, show notable success in preventing invasive diseases and declining incidence in high-risk groups.
Area of Science:
- Infectious Diseases
- Vaccinology
- Public Health
Background:
- Bacterial meningitis poses a significant global health threat, causing high mortality and morbidity.
- Available vaccines have demonstrated efficacy in reducing the incidence of bacterial meningitis.
Purpose of the Study:
- To review the impact of available vaccines on bacterial meningitis.
- To highlight the success of conjugate vaccines in disease prevention.
Main Methods:
- Literature review of vaccine efficacy studies.
- Analysis of incidence data for vaccine-preventable meningitis.
Main Results:
- Haemophilus influenzae type B conjugate vaccine effectively reduces meningitis incidence.
- The 7-valent pneumococcal conjugate vaccine (PCV) dramatically reduced invasive pneumococcal disease.
- Quadrivalent meningococcal conjugate vaccine shows declining incidence in high-risk and endemic areas.
Conclusions:
- Vaccination strategies are crucial for controlling bacterial meningitis.
- Conjugate vaccines represent a major advancement in preventing severe bacterial infections.
- Continued surveillance is necessary to monitor vaccine impact and emerging serotypes.
More Related Videos
Related Concept Videos
Bacterial Meningitis I: Introduction
Bacterial Meningitis
Bacterial Meningitis II: Pathophysiology
Viral Meningitis
Microorganisms in Medicine and Therapeutics
Vaccines

